SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE

西南肿瘤学集团 - 运营办公室

基本信息

批准号：
7933285
负责人：
LAURENCE HOWARD BAKER
金额：
$ 69万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2011-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7933285
关键词：
Achievement Adjuvant Adult Advocate African American Anthracyclines Asian Americans Biological Assay Canada Cancer Patient Cancer Survivor Cancer Therapy Evaluation Program Clinical Clinical Research Clinical Trials Community Clinical Oncology Program Conflict of Interest Cyclophosphamide Development Disease Disease-Free Survival Doxorubicin Education Ethics Fluorouracil Funding Gynecology Hispanic Americans Hospitals Institution Laboratory Research Malignant Female Reproductive System Neoplasm Malignant Neoplasms Medical Oncology Methods Minority Minority Groups Modality Monitor Morals Online Systems Operative Surgical Procedures Outcome Patients Performance Phase Policies Population Positive Lymph Node Postmenopause Prevention Prognostic Factor Publications Randomized Reporting Research Research Personnel Resources Role Safety Science Southwest Oncology Group System Tamoxifen Technology Therapeutic Therapeutics Committee Training Tumor Bank Urologic Cancer Woman anticancer research base cancer prevention chemotherapy data integrity high risk innovation malignant breast neoplasm member named group older men outreach program prevent programs quality assurance response sarcoma sound statistical center

项目摘要

DESCRIPTION (provided by applicant): The Southwest Oncology Group is an adult, multi-disease, multi-modality clinical cancer research organization with 35 Member Institutions, 29 Community Clinical Oncology Program (CCOP) institutions, including 7 Minority-Based CCOPs, 27 Urologic Cancer Outreach Program (UCOP) members, and a network of 1,036 Affiliate Program investigators at 189 offices and hospitals, and 12 institutions participating in the CTEP Minority program. A special emphasis of the Group is managed by the renamed Committee on Special Populations, established in 1992. The committee's research and education agenda has broadened to include: women (or men), older cancer patients, cancer survivors, and racial/ethnic minority groups (African-American, Hispanic Americans and Asian American Pacific Islanders). Involving patient advocates in Group activities is an important role of this committee. The committee report details the cross-committee research and publications. The moral and ethical conduct of clinical research by the group members is emphasized by ethics training, the conflict of interest policy, affirmation of integrity and data and safety monitoring. In addition to the presentation of correlative sciences activities tied to tumor banks related to disease committees, we propose a Correlative Sciences Committee, which will provide oversight of science and quality assurance of assay technology across the six disease committee correlative science programs in the Group. There are three new initiatives in this application. Two new adult medical oncology Intergroup proposals, one dealing with advanced gynecologic cancer, the U.S. Gynecology Intergroup, and the second dealing with sarcomas, The U.S./Canada Sarcoma Intergroup. The third is the Early Therapeutics Committee, which will take advantage of the 10 institutions in the Group who hold Phase I NCI funded U-01s. This will be possible with the new Web-Based, Multi-User Phase I Monitoring System implemented by our Statistical Center.

描述（由申请人提供）：西南肿瘤学组是一个成人、多疾病、多模式的临床癌症研究组织，拥有 35 个成员机构、29 个社区临床肿瘤学项目 (CCOP) 机构，其中包括 7 个少数族裔 CCOP、27 个泌尿科机构癌症外展计划 (UCOP) 成员，以及由 189 个办公室和医院以及 12 个参与机构的 1,036 名附属计划调查员组成的网络在 CTEP 少数族裔计划中。该小组的一个特别重点是由 1992 年成立的更名为特殊人群委员会管理。该委员会的研究和教育议程已扩大到包括：女性（或男性）、老年癌症患者、癌症幸存者和少数种族/族裔群体（非裔美国人、西班牙裔美国人和亚裔美国人太平洋岛民）。让患者权益倡导者参与团体活动是该委员会的重要作用。委员会报告详细介绍了跨委员会的研究和出版物。通过道德培训、利益冲突政策、诚信和数据确认以及安全监控，强调小组成员临床研究的道德和伦理行为。除了介绍与疾病委员会相关的肿瘤库相关的相关科学活动外，我们还提议设立一个相关科学委员会，该委员会将为集团内六个疾病委员会相关科学项目提供科学监督和检测技术的质量保证。该应用程序中有三项新举措。两项新的成人医学肿瘤学跨组提案，一项涉及晚期妇科癌症，即美国妇科跨组，第二项涉及肉瘤，即美国/加拿大肉瘤跨组。第三个是早期治疗委员会，该委员会将利用集团内持有 I 期 NCI 资助的 U-01 的 10 家机构。通过我们的统计中心实施的新的基于网络的多用户第一阶段监测系统，这将成为可能。